Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

OBJECTIVE: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Metab Syndr Obes
Autors principals: Davies, Michael J, Merton, Katherine W, Vijapurkar, Ujjwala, Balis, Dainius A, Desai, Mehul
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291455/
https://ncbi.nlm.nih.gov/pubmed/28184166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S126291
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars